DUBLIN–(BUSINESS WIRE)–The “Australia CBD Sector: How Would the Recent Proposal to Change the Scheduling for CBD Affect your Business?” report has been added to ResearchAndMarkets.com’s offering.
CBD is listed on the Controlled Drug Register in Australia, which means that it can’t be sold as a consumer product.
From June 2021, the Therapeutic Goods Administration has enabled access to such products through pharmacies, and without a prescription. This report provides a detailed overview of the current regulatory regime in place in Australia for these products, covering everything from the hemp plant itself to extracts and finished products.
A proposal has been put forward that would change the scheduling of CBD, which in turn has a number of consequences. If this, and the Australian market in general, interests you then this is the report for you.
It not only provides information on the current regulatory regime for hemp and CBD in Australia, but it also offers analysis and data about the near future, as well as insight into the current status of medical and recreational cannabis.
Key Topics Covered:
- Hemp plant
- The hemp plant definition
- Requirements to grow
- Extracts as finished products
- CBD isolates
- Full/broad spectrum
Finished products containing CBD and extracts
- Cosmetic products
- Vaping products
- Pet food
- CBD isolates and full spectrum
- Finished products
- Access to cannabis-based medicinal products
- Production of medical cannabis (high THC plants/flowers)
- Near future
- Relevant bodies
For more information about this report visit https://www.researchandmarkets.com/r/vywtbi